2027 CDMO Leadership Awards

Independent, client-informed recognition

CDMO Leadership Awards

The CDMO Leadership Awards recognize contract development and manufacturing organizations based on direct feedback from biopharma companies that have worked with them. Recognition reflects real-world outsourcing performance, not submissions or self-nominations.

Presented by Outsourced Pharma Life Science Connect
Research by Tufts Center for the Study of Drug Development

About the awards

Recognition based on verified client feedback.

Each year, biopharma professionals involved in outsourcing decisions rate the CDMOs they've worked with. The awards recognize the organizations those clients rate highest for overall performance and partnership.

CDMO of the Year

The highest level of client-rated recognition within each modality and size category, based on aggregated survey results.

Best in Class

Calculated from the same survey data. Recognizes top performance in specific attributes like project management, cultural fit, and scaling support.

Strengthening rigor and transparency

Starting with the 2026 awards, the program is conducted in research partnership with the Tufts Center for the Study of Drug Development. Tufts CSDD provides independent oversight of survey design, respondent validation, and analysis. CDMOs can't self-nominate, submit materials, or influence scoring.

2027 awards survey

Share your CDMO experience.

Tufts CSDD is collecting candid feedback from pharmaceutical and biotechnology professionals about their experiences with their CDMO partners. Results will be used to recognize CDMOs that provide outstanding relationships and services. All responses are confidential and reported only in the aggregate.

Do you work with CDMOs?

If you work at a pharmaceutical or biotechnology company and have firsthand experience with the CDMOs you evaluate, we'd love to hear from you. Every response helps.

Take the survey

Are you a CDMO?

You can invite your eligible clients to share their experience. The survey toolkit has the survey link, a ready-to-send invitation, and the participation guidelines.

Get the survey toolkit

Integrity comes first

  • Only eligible clients should complete the survey, based on their own firsthand experience.
  • CDMO employees shouldn't take the survey or respond on behalf of clients.
  • No directing scores, duplicate submissions, or incentives tied to participation or ratings.

Tufts CSDD reviews submissions for integrity. CDMOs tied to improper activity may be disqualified.

Methodology

How the awards are determined.

The methodology prioritizes independence, consistency, and client-led evaluation, so recognition reflects real-world performance rather than submissions, nominations, or promotional activity.

Independent research oversight

Tufts CSDD is responsible for:

  • Survey design and structure
  • Respondent qualification and validation
  • Statistical analysis and methodological rigor

Life Science Connect administers the program and publishes the findings but doesn't select winners or influence scoring.

Respondent eligibility

Survey responses come from qualified biopharma professionals who:

  • Are directly involved in outsourcing decisions or oversight
  • Have worked with the CDMO they're evaluating within the past 18 to 24 months
  • Evaluate only CDMOs they've personally worked with

Respondents may evaluate multiple CDMOs if they meet these criteria for each relationship.

What CDMOs can't do

  • Self-nominate
  • Submit materials
  • Decide who qualifies to take the survey
  • Influence scoring or outcomes

Program independence

CDMOs aren't eligible to sponsor the program. Sponsorship is limited to non-CDMO organizations and doesn't influence survey design, scoring, shortlists, or award recipients.

Survey structure and supporting inputs

Primary metric

The primary award metric is a 0 to 10 likelihood-to-recommend score for each CDMO a respondent has worked with during the eligibility period. It reflects the respondent's overall assessment of the CDMO as an outsourcing partner.

Supporting performance inputs

Respondents also rate CDMOs across performance dimensions, including development capabilities, manufacturing performance, delivery and reliability, and ongoing support and collaboration.

They also identify best-in-class performance for attributes such as technical expertise, on-time delivery, innovation, facilities and infrastructure, and quality systems. These inputs add context but don't replace the primary recommendation score.

Scoring model and thresholds

The awards use a proprietary scoring model that blends likelihood-to-recommend scores, supporting satisfaction ratings, and best-in-class attribute rankings.

Minimum thresholds apply, including a minimum number of qualified responses per CDMO and minimum score thresholds within each modality and cohort. Only CDMOs that meet both response-count and score thresholds are eligible for recognition.

Modalities, cohorts, and size categories

CDMOs are evaluated within defined modalities and regional cohorts. These may include, but aren't limited to, biologics, cell and gene therapy, small-molecule API, and small-molecule dosage forms.

CDMOs are grouped into two revenue-based categories, Large and Small/Mid-Sized, so companies are evaluated among similar peers. $1B in CDMO revenue is the threshold between the two groups.

Continuity and evolution

The methodology builds on the recommendation-based framework used in prior years while adding independent research oversight. Core principles stay the same: client-led evaluation, verified respondent qualification, clear scoring thresholds, and separation between survey results and commercial activity.

Our research partner

Tufts Center for the Study of Drug Development

Research conducted in partnership with Tufts CSDD

The Tufts Center for the Study of Drug Development is an independent, academic, nonprofit research group at Tufts University. Since 1976, Tufts CSDD has produced robust, data-driven assessments, analysis, and insight focused on improving drug development performance, efficiency, and economics.

Tufts CSDD independently manages respondent qualification and survey analysis for the CDMO Leadership Awards.

2026 finalists and winners

Congratulations to the 2026 honorees.

The 2026 finalists and winners were selected based on direct feedback from biopharma decision makers and independently analyzed by Tufts CSDD. Thank you to the sponsors who helped make this year's celebration possible.

Large and Small/Mid-Sized categories use $1B in CDMO revenue as the threshold.

CDMO of the Year

Biologic CDMO of the Year

Large CDMOs

WuXi Biologics

Finalists: AbbVie, Samsung Biologics

Small/Mid-Sized CDMOs

Eurofins

Finalists: KBI Biopharma, Pharmaron

Cell & Gene Therapy CDMO of the Year

Large CDMOs

MilliporeSigma

Finalists: Lonza, Recipharm

Small/Mid-Sized CDMOs

Aldevron

Finalist: Ajinomoto Bio-Pharma Services

Small Molecule API CDMO of the Year

Large CDMOs

Lonza

Finalists: Almac, WuXi STA

Small/Mid-Sized CDMOs

Asymchem

Finalists: Esteve CDMO, Pharmaron

Small Molecule Finished Dose CDMO of the Year

Sponsored by MasterControl

Large CDMOs

Vetter Pharma

Finalists: Lonza, WuXi STA

Small/Mid-Sized CDMOs

Bend Bioscience

Finalists: Corden Pharma, Pharmaron

Fill-Finish CDMO of the Year

Large CDMOs

AbbVie

Finalists: Vetter Pharma, WuXi Biologics

Small/Mid-Sized CDMOs

KBI Biopharma

Finalists: Eurofins, Syngene International

Best in Class

Top performers in each Best in Class attribute by modality and company size. Select a category to see results.

Large Biologic
AttributeWinnerFinalists
Analytical ServicesWuXi BiologicsMilliporeSigma, Lonza
Overall StaffWuXi BiologicsAbbVie, Samsung Biologics
Project ManagementWuXi BiologicsSamsung Biologics, AbbVie
Cultural FitSamsung BiologicsAbbVie, WuXi Biologics
Technology UseMilliporeSigmaWuXi Biologics, AbbVie
Scaling SupportWuXi BiologicsAbbVie, Samsung Biologics
Large Cell & Gene Therapy
AttributeWinnerFinalists
Analytical ServicesMilliporeSigmaRecipharm, FUJIFILM Biotechnologies
Overall StaffMilliporeSigmaRecipharm, Thermo Fisher Scientific
Project ManagementMilliporeSigmaRecipharm, Lonza
Cultural FitMilliporeSigmaLonza, Recipharm
Technology UseMilliporeSigmaRecipharm, Lonza
Scaling SupportRecipharmThermo Fisher Scientific, MilliporeSigma
Large Small Molecule API
AttributeWinnerFinalists
Analytical ServicesLonzaMilliporeSigma, WuXi STA
Overall StaffLonzaMilliporeSigma, Curia
Project ManagementLonzaCuria, Almac
Cultural FitLonzaAlmac, MilliporeSigma
Technology UseMilliporeSigmaLonza, Almac
Scaling SupportCuriaWuXi STA, Almac
Large Small Molecule Finished Dose
AttributeWinnerFinalists
Analytical ServicesVetter PharmaWuXi STA, Lonza
Overall StaffVetter PharmaLonza, Catalent
Project ManagementVetter PharmaLonza, Catalent
Cultural FitLonzaVetter Pharma, Catalent
Technology UseVetter PharmaLonza, Thermo Fisher Scientific
Scaling SupportWuXi STACatalent, Thermo Fisher Scientific
Small/Mid-Sized Biologic
AttributeWinnerFinalists
Analytical ServicesSimtra BioPharma SolutionsPharmaron, KBI Biopharma
Overall StaffSimtra BioPharma SolutionsKBI Biopharma, IDT Biologika
Project ManagementSimtra BioPharma SolutionsAbzena, KBI Biopharma
Cultural FitKBI BiopharmaAGC Biologics, Eurofins
Technology UseSimtra BioPharma SolutionsKBI Biopharma, Abzena
Scaling SupportSimtra BioPharma SolutionsAGC Biologics, PCI Pharma Services
Small/Mid-Sized Cell & Gene Therapy
AttributeWinnerFinalists
Analytical ServicesAldevronAGC Biologics, IDT Biologika
Overall StaffAldevronIDT Biologika, Ajinomoto Bio-Pharma Services
Project ManagementAldevronIDT Biologika, Ajinomoto Bio-Pharma Services
Cultural FitAldevronIDT Biologika, Ajinomoto Bio-Pharma Services
Technology UseAldevronIDT Biologika, Cellipont
Scaling SupportAldevronIDT Biologika, Ajinomoto Bio-Pharma Services
Small/Mid-Sized Small Molecule API
AttributeWinnerFinalists
Analytical ServicesAlcamiAGC Pharma Chemicals, Pharmaron
Overall StaffAGC Pharma ChemicalsVeranova, Asymchem
Project ManagementVeranovaAGC Pharma Chemicals
Cultural FitAGC Pharma ChemicalsVeranova, Esteve
Technology UseAGC Pharma ChemicalsEsteve, Asymchem
Scaling SupportAGC Pharma ChemicalsAsymchem, Veranova
Small/Mid-Sized Small Molecule Finished Dose
AttributeWinnerFinalists
Analytical ServicesAsymchemBend Bioscience, Alcami
Overall StaffGrifols International S.A.Asymchem, Corden Pharma
Project ManagementGrifols International S.A.Corden Pharma, Asymchem
Cultural FitGrifols International S.A.Corden Pharma, Asymchem
Technology UseCorden PharmaAsymchem, Pharmaron
Scaling SupportGrifols International S.A.Asymchem, Corden Pharma
2026 Jury Awards

Jury Awards were selected by an independent panel of industry leaders in 2026. They aren't part of the 2027 program.

AwardWinnerFinalists
Most Innovative CDMO, Small MoleculeEsteve CDMOCarbogen Amcis, Upperton Pharma Solutions, Veranova
Most Innovative CDMO, BiologicsFUJIFILM BiotechnologiesAGC Biologics, Just-Evotec Biologics, Rentschler Biopharma
Most Innovative CDMO, Cell & Gene TherapyOXBNorthX Biologics, ProBioGen, Viralgen
Best New or Relaunched CDMOLotte BiologicsArdena, Axplora, Biovectra, Minaris Advanced Therapies, Rezon Bio, Simtra BioPharma Solutions
Best CDMO Management TeamSiegfried3PBiovian, Dottikon, Grand River Aseptic Manufacturing, IDT Biologika
Best Private Equity Team Supporting the CDMO IndustryGHO Capital1315 Capital, EQT, Permira, Thomas H. Lee Partners, Warburg Pincus
Sustainability Leadership AwardSamsung BiologicsBoehringer Ingelheim BioXcellence, Lonza, Thermo Fisher Scientific, Vetter Pharma
2026 Lifetime Achievement Award

Derek Hennecke, recognized for more than three decades of leadership in the CDMO industry.

Sponsorship

Connect with senior CDMO and biopharma decision makers.

The CDMO Leadership Awards bring together senior CDMO and biopharma leaders during DCAT Week and key global industry moments. Sponsorship supports the program and recognition events while preserving the independence of the awards.

Why sponsors take part

  • Targeted visibility among senior executives attending DCAT Week and related events
  • A curated audience responsible for outsourcing strategy, manufacturing, external partnerships, and supply chain decisions
  • Brand alignment with recognized CDMO performance
  • Post-event visibility across Life Science Connect and Outsourced Pharma channels

2027 sponsorship paths

  • Title sponsorship of the awards ceremony and reception, for one company seeking elevated visibility and priority access
  • Award sponsorships for CDMO of the Year and Best in Class, including presenting the award on stage
  • Experience sponsorships tied to high-traffic onsite moments
  • Brand presence, media, and custom options for focused visibility during and after the event

The 2027 ceremony takes place Wednesday, March 17, 2027, at The Pool in New York City during DCAT Week. Early commitment opportunities are available for select sponsorships.

Representative companies and roles

Registrants span executive leadership, business development, manufacturing, procurement, and external supply functions, with most attendees at the executive, vice president, and director level.

  • AGC Biologics | Chief Executive Officer
  • Ajinomoto Bio-Pharma Services | President & COO
  • Aenova | Chief Commercial Officer
  • BIOVECTRA | Chief Commercial Officer
  • Oxford Biomedica | Chief Business Officer
  • Thermo Fisher Scientific | President, Commercial Operations
  • Piramal Pharma Solutions | Chief Operating Officer
  • Siegfried | Chief Scientific Officer
  • WuXi Biologics | Senior Vice President, Global CMC
  • Lonza | EVP, Head of Mammalian Business Unit
  • Porton Pharma Solutions | SVP, Business Development, Europe
  • Avid Bioservices | Senior Director, Business Development
  • PCI Pharma Services | VP, Business Development, North America
  • Aenova | VP, Global Business Development
  • Bionova Scientific | VP, Business Development
  • Nanoform | VP, Business Development
  • Biogen | Director, External Network Strategy
  • BIOVECTRA | Director, Procurement
  • CordenPharma International | Senior Platform Director
  • Esteve | Global Head of Commercial Operations & Strategy
  • Boehringer Ingelheim Biopharmaceuticals | Director, Key Account Management
  • Pfizer CentreOne | Director, Network Strategy

Next steps

If you work with a Life Science Connect account manager, reach out to them to talk through fit, availability, and timing. Full details on levels, deliverables, and timelines are in the prospectus.

Download the 2027 sponsorship prospectus (PDF)

Sponsorship doesn't affect survey methodology, scoring, shortlists, or winners. We can't provide survey access or accept submissions or materials from CDMOs.

Life Science Connect Outsourced Pharma Tufts Center for the Study of Drug Development

Life Science Connect | 210 W Kensinger Drive, Suite 500, Cranberry Township, PA 16066 | 724-940-7555
Follow along: Outsourced Pharma on LinkedIn

CDMO Leadership Awards · Presented by Outsourced Pharma and Life Science Connect
Research conducted in partnership with Tufts CSDD